Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q1 2014 · 10-Q
Revenue—
Net Income-$3.45M-$3.45MN/M vs Q1 2013 EPS Diluted-$0.08-$0.08N/M vs Q1 2013 Operating Income-$3,464,000N/M Operating Cash Flow-$2,723,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,802,000— ended Mar 31, 2014 · filed May 7, 2014 · 37 d after period end